Gisbert Selke

2.7k total citations
20 papers, 765 citations indexed

About

Gisbert Selke is a scholar working on Economics and Econometrics, Pediatrics, Perinatology and Child Health and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Gisbert Selke has authored 20 papers receiving a total of 765 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Economics and Econometrics, 6 papers in Pediatrics, Perinatology and Child Health and 5 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Gisbert Selke's work include Pharmaceutical Economics and Policy (7 papers), Health Systems, Economic Evaluations, Quality of Life (5 papers) and Pharmaceutical studies and practices (5 papers). Gisbert Selke is often cited by papers focused on Pharmaceutical Economics and Policy (7 papers), Health Systems, Economic Evaluations, Quality of Life (5 papers) and Pharmaceutical studies and practices (5 papers). Gisbert Selke collaborates with scholars based in Germany, Sweden and United Kingdom. Gisbert Selke's co-authors include Ralf Bender, Christian Günster, P. T. Sawicki, Lars G. Hemkens, S. Gutschmidt, Ulrich Grouven, Livio Garattini, Giovanni Giuliani, Brian Godman and Sebastian Schneeweiß and has published in prestigious journals such as Diabetologia, Frontiers in Pharmacology and British Journal of Clinical Pharmacology.

In The Last Decade

Gisbert Selke

20 papers receiving 726 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gisbert Selke Germany 10 366 277 202 158 127 20 765
Véronique Turcotte Canada 15 240 0.7× 126 0.5× 60 0.3× 91 0.6× 43 0.3× 39 825
C. J. Currie United Kingdom 10 821 2.2× 687 2.5× 67 0.3× 386 2.4× 256 2.0× 15 1.4k
Jetty A. Overbeek Netherlands 14 138 0.4× 298 1.1× 46 0.2× 112 0.7× 115 0.9× 57 716
J. van de Ven Netherlands 15 170 0.5× 78 0.3× 29 0.1× 144 0.9× 67 0.5× 26 992
Joshua Ray Switzerland 15 53 0.1× 327 1.2× 294 1.5× 90 0.6× 78 0.6× 45 875
Nancy Reynoso‐Noverón Mexico 14 80 0.2× 145 0.5× 50 0.2× 179 1.1× 59 0.5× 67 716
J. Gregory Boyer United States 7 109 0.3× 137 0.5× 99 0.5× 40 0.3× 48 0.4× 19 573
Marjel van Dam Netherlands 13 484 1.3× 261 0.9× 40 0.2× 476 3.0× 975 7.7× 29 1.3k
Sarah Goring United States 15 104 0.3× 114 0.4× 93 0.5× 154 1.0× 80 0.6× 37 613

Countries citing papers authored by Gisbert Selke

Since Specialization
Citations

This map shows the geographic impact of Gisbert Selke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gisbert Selke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gisbert Selke more than expected).

Fields of papers citing papers by Gisbert Selke

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gisbert Selke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gisbert Selke. The network helps show where Gisbert Selke may publish in the future.

Co-authorship network of co-authors of Gisbert Selke

This figure shows the co-authorship network connecting the top 25 collaborators of Gisbert Selke. A scholar is included among the top collaborators of Gisbert Selke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gisbert Selke. Gisbert Selke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Holko, Przemysław, Rafał Nowak, Marc Dooms, et al.. (2024). Clinical and non-clinical aspects of reimbursement policy for orphan drugs in selected European countries. Frontiers in Pharmacology. 15. 1498386–1498386. 2 indexed citations
2.
Köster, Ingrid, et al.. (2023). Prescribing of valproate and oral antiepileptics for women of childbearing age and during pregnancy in Germany between 2010 and 2020. Pharmacoepidemiology and Drug Safety. 32(11). 1306–1314. 4 indexed citations
3.
Krulichová, Iva Selke, Gisbert Selke, Marion Bennie, et al.. (2022). Comparison of drug prescribing before and during the COVID‐19 pandemic: A cross‐national European study. Pharmacoepidemiology and Drug Safety. 31(10). 1046–1055. 26 indexed citations
4.
Krulichová, Iva Selke, Gisbert Selke, & Petra Thürmann. (2021). Trends and patterns in EU(7)-PIM prescribing to elderly patients in Germany. European Journal of Clinical Pharmacology. 77(10). 1553–1561. 8 indexed citations
5.
Moorkens, Evelien, Arnold G. Vulto, Martin Schulz, et al.. (2020). Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany. Pharmaceuticals. 13(10). 324–324. 22 indexed citations
6.
7.
Bezrouk, Aleš, et al.. (2017). Nickel-Titanium Closed-coil Springs. Evaluation of the clinical plateau. Revista de Chimie. 68(5). 1137–1142. 2 indexed citations
8.
Godman, Brian, Hanne Bak Pedersen, Jurij Fürst, et al.. (2015). Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe. Expert Review of Pharmacoeconomics & Outcomes Research. 15(5). 755–758. 28 indexed citations
9.
Campbell, Stephen, Brian Godman, Eduardo Diogène, et al.. (2014). Quality Indicators as a Tool in Improving the Introduction of New Medicines. Basic & Clinical Pharmacology & Toxicology. 116(2). 146–157. 20 indexed citations
10.
Godman, Brian, et al.. (2012). Improving the managed entry of new medicines: sharing experiences across Europe. Expert Review of Pharmacoeconomics & Outcomes Research. 12(4). 439–441. 40 indexed citations
11.
Bohlken, Jens, Gisbert Selke, & Hendrik van den Bussche. (2011). Antidementivaverordnungen in Stadt und Land – Ein Vergleich zwischen Ballungszentren und Flächenstaaten in Deutschland. Psychiatrische Praxis. 38(5). 232–236. 8 indexed citations
12.
Hemkens, Lars G., Ulrich Grouven, Ralf Bender, et al.. (2009). Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 52(9). 1732–1744. 435 indexed citations
13.
Ufer, Mike, Olaf Junge, Gisbert Selke, et al.. (2007). Patterns and prevalence of antidepressant drug use in the German state of Baden‐Wuerttemberg: a prescription‐based analysis. Pharmacoepidemiology and Drug Safety. 16(10). 1153–1160. 29 indexed citations
14.
Sawicki, Peter T., et al.. (2006). Schätzung der unter Rofecoxib (Vioxx®) in Deutschland in den Jahren 2001–2004 aufgetretenen kardio- und zerebrovaskulären Ereignisse. Medizinische Klinik. 101(3). 191–197. 5 indexed citations
15.
16.
Ponti, Fabrizio De, Elisabetta Poluzzi, Alberto Vaccheri, et al.. (2002). Non‐antiarrhythmic drugs prolonging the QT interval:considerable use in seven countries. British Journal of Clinical Pharmacology. 54(2). 171–177. 29 indexed citations
17.
Klauber, Jürgen, et al.. (2000). Innovation im Arzneimittelmarkt. 2 indexed citations
18.
Schneeweiß, Sebastian, Oliver Schöffski, & Gisbert Selke. (1998). What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?. Health Policy. 44(3). 253–260. 34 indexed citations
19.
Giuliani, Giovanni, Gisbert Selke, & Livio Garattini. (1998). The German experience in reference pricing. Health Policy. 44(1). 73–85. 63 indexed citations
20.
Selke, Gisbert, et al.. (1990). Auswirkungen der Arzneimittelfestbeträge. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Véronique Turcotte Breakdown of academic impact, for papers by C. J. Currie Breakdown of academic impact, for papers by Jetty A. Overbeek Breakdown of academic impact, for papers by J. van de Ven Breakdown of academic impact, for papers by Joshua Ray Breakdown of academic impact, for papers by Nancy Reynoso‐Noverón Breakdown of academic impact, for papers by J. Gregory Boyer Breakdown of academic impact, for papers by Marjel van Dam Breakdown of academic impact, for papers by Sarah Goring
Rankless by CCL
2026